Clenoliximab
From Wikipedia, the free encyclopedia
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (primate/human) |
Target | CD4 |
Clinical data | |
Legal status | ? |
Identifiers | |
ATC code | None |
Chemical data | |
Formula | ? |
(what is this?) (verify) | |
Clenoliximab (INN[1]) is a monoclonal antibody against CD4. It acts as an immunomodulator and has been investigated for the treatment of rheumatoid arthritis.[2] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[1]
References
- ↑ 1.0 1.1 World Health Organization (1997). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77". WHO Drug Information 11 (2): 89.
- ↑ Hepburn, TW; Totoritis, MC; Davis, CB (2003). "Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis.". Rheumatology (Oxford, England) 42 (1): 54–61. doi:10.1093/rheumatology/keg030. PMID 12509613.
|
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.